{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T17:02:37Z","timestamp":1784998957829,"version":"3.55.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100020107","name":"Hirose Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020107","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s10147-026-03086-z","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T11:39:39Z","timestamp":1781005179000},"page":"1721-1731","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Exploring plasma cell-free RNA biomarkers for predicting immune checkpoint inhibitor efficacy in gastric cancer: a translational sub-study of the KSCC VOYAGER phase II trial"],"prefix":"10.1007","volume":"31","author":[{"given":"Shinichiro","family":"Ikeda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8313-5861","authenticated-orcid":false,"given":"Qingjiang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keita","family":"Natsugoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuro","family":"Kawazoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomomi","family":"Kashiwada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akitaka","family":"Makiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Oki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinao","family":"Oda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoharu","family":"Yoshizumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,9]]},"reference":[{"key":"3086_CR1","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/S1470-2045(21)00692-6","volume":"23","author":"YK Kang","year":"2022","unstructured":"Kang YK, Chen LT, Ryu MH et al (2022) Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 23:234\u2013237. https:\/\/doi.org\/10.1016\/S1470-2045(21)00692-6","journal-title":"Lancet Oncol"},{"key":"3086_CR2","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M et al (2021) First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet 398:27\u201340. https:\/\/doi.org\/10.1016\/S0140-6736(21)00797-2","journal-title":"Lancet"},{"key":"3086_CR3","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","volume":"24","author":"SY Rha","year":"2023","unstructured":"Rha SY, Oh DY, Ya\u00f1ez P et al (2023) Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 24:1181\u20131195. https:\/\/doi.org\/10.1016\/S1470-2045(23)00515-6","journal-title":"Lancet Oncol"},{"key":"3086_CR4","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s00595-020-02148-7","volume":"51","author":"K Shoda","year":"2021","unstructured":"Shoda K, Saito R, Maruyama S et al (2021) Liquid biopsy as a perioperative biomarker of digestive tract cancers: review of the literature. Surg Today 51:849\u2013861. https:\/\/doi.org\/10.1007\/s00595-020-02148-7","journal-title":"Surg Today"},{"key":"3086_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22444-1","volume":"12","author":"MH Larson","year":"2021","unstructured":"Larson MH, Pan W, Kim HJ et al (2021) A comprehensive characterization of the cell-free transcriptome reveals tissue- and subtype-specific biomarkers for cancer detection. Nat Commun 12:2357. https:\/\/doi.org\/10.1038\/s41467-021-22444-1","journal-title":"Nat Commun"},{"key":"3086_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-62685-y","volume":"16","author":"TW Moore","year":"2025","unstructured":"Moore TW, Spiliotopoulos E, Callahan RL et al (2025) Cell free RNA detection of pancreatic cancer in pre diagnostic high risk and symptomatic patients. Nat Commun 16:7345. https:\/\/doi.org\/10.1038\/s41467-025-62685-y","journal-title":"Nat Commun"},{"key":"3086_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmogo.2025.100148","volume":"8","author":"A Makiyama","year":"2025","unstructured":"Makiyama A, Hu Q, Nagasaka T et al (2025) T-cell invigoration to cell-free DNA ratio associated with anti-PD-1 response in gastric or gastro-esophageal junction adenocarcinoma: VOYAGER trial. ESMO Gastrointest Oncol 8:100148. https:\/\/doi.org\/10.1016\/j.esmogo.2025.100148","journal-title":"ESMO Gastrointest Oncol"},{"key":"3086_CR8","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1038\/s41379-021-00823-9","volume":"34","author":"S Ahn","year":"2021","unstructured":"Ahn S, Kim KM (2021) PD-L1 expression in gastric cancer: interchangeability of 22C3 and 28-8 pharmDx assays for responses to immunotherapy. Mod Pathol 34:1719\u20131727. https:\/\/doi.org\/10.1038\/s41379-021-00823-9","journal-title":"Mod Pathol"},{"key":"3086_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/1755-8794-2-18","volume":"2","author":"H Mizuno","year":"2009","unstructured":"Mizuno H, Kitada K, Nakai K et al (2009) PrognoScan: a new database for meta-analysis of the prognostic value of genes. BMC Med Genomics 2:18. https:\/\/doi.org\/10.1186\/1755-8794-2-18","journal-title":"BMC Med Genomics"},{"key":"3086_CR10","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nmeth.3337","volume":"12","author":"AM Newman","year":"2015","unstructured":"Newman AM, Liu CL, Green MR et al (2015) Robust enumeration of cell subsets from tissue expression profiles. Nat Methods 12:453\u2013457. https:\/\/doi.org\/10.1038\/nmeth.3337","journal-title":"Nat Methods"},{"key":"3086_CR11","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1038\/s41591-018-0101-z","volume":"24","author":"ST Kim","year":"2018","unstructured":"Kim ST, Cristescu R, Bass AJ et al (2018) Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nat Med 24:1449\u20131458. https:\/\/doi.org\/10.1038\/s41591-018-0101-z","journal-title":"Nat Med"},{"key":"3086_CR12","doi-asserted-by":"publisher","first-page":"177","DOI":"10.5230\/jgc.2025.25.e4","volume":"25","author":"Y Cho","year":"2025","unstructured":"Cho Y, Ahn S, Kim KM (2025) PD-L1 as a biomarker in gastric cancer immunotherapy. J Gastric Cancer 25:177\u2013191. https:\/\/doi.org\/10.5230\/jgc.2025.25.e4","journal-title":"J Gastric Cancer"},{"key":"3086_CR13","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/S0140-6736(17)31827-5","volume":"390","author":"YK Kang","year":"2017","unstructured":"Kang YK, Boku N, Satoh T et al (2017) Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390:2461\u20132471. https:\/\/doi.org\/10.1016\/S0140-6736(17)31827-5","journal-title":"Lancet"},{"key":"3086_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-44461-y","volume":"15","author":"J Wang","year":"2024","unstructured":"Wang J, Huang J, Hu Y et al (2024) Terminal modifications independent cell-free RNA sequencing enables sensitive early cancer detection and classification. Nat Commun 15:156. https:\/\/doi.org\/10.1038\/s41467-023-44461-y","journal-title":"Nat Commun"},{"key":"3086_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/wrna.179","volume":"14","author":"S Xing","year":"2023","unstructured":"Xing S, Zhu Y, You Y et al (2023) Cell-free RNA for the liquid biopsy of gastrointestinal cancer. Wiley Interdiscip Rev RNA 14:e1791. https:\/\/doi.org\/10.1002\/wrna.179","journal-title":"Wiley Interdiscip Rev RNA"},{"key":"3086_CR16","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41576-018-0071-5","volume":"20","author":"E Heitzer","year":"2019","unstructured":"Heitzer E, Haque IS, Roberts CES et al (2019) Current and future perspectives of liquid biopsies in genomics-driven oncology. Nat Rev Genet 20:71\u201388. https:\/\/doi.org\/10.1038\/s41576-018-0071-5","journal-title":"Nat Rev Genet"},{"key":"3086_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0308711","volume":"19","author":"EJ Northrop-Albrecht","year":"2024","unstructured":"Northrop-Albrecht EJ, Wu CW, Berger CK et al (2024) An investigation of plasma cell-free RNA for the detection of colorectal cancer: from transcriptome marker selection to targeted validation. PLoS ONE 19:e0308711. https:\/\/doi.org\/10.1371\/journal.pone.0308711","journal-title":"PLoS ONE"},{"key":"3086_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinbiochem.2023.05.002","volume":"118","author":"KE Mullins","year":"2023","unstructured":"Mullins KE, Seneviratne C, Shetty AC et al (2023) Proof of concept: detection of cell free RNA from EDTA plasma in patients with lung cancer and non-cancer patients. Clin Biochem 118:110583. https:\/\/doi.org\/10.1016\/j.clinbiochem.2023.05.002","journal-title":"Clin Biochem"},{"key":"3086_CR19","doi-asserted-by":"publisher","first-page":"439","DOI":"10.3727\/0965040041791473","volume":"14","author":"E Papadopoulou","year":"2004","unstructured":"Papadopoulou E, Davilas E, Sotiriou V et al (2004) Cell-free DNA and RNA in plasma as a new molecular marker for prostate cancer. Oncol Res 14:439\u2013445. https:\/\/doi.org\/10.3727\/0965040041791473","journal-title":"Oncol Res"},{"key":"3086_CR20","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1038\/s41588-024-01899-0","volume":"56","author":"J Usset","year":"2024","unstructured":"Usset J, Rosendahl Huber A, Andrianova MA et al (2024) Five latent factors underlie response to immunotherapy. Nat Genet 56:2112\u20132120. https:\/\/doi.org\/10.1038\/s41588-024-01899-0","journal-title":"Nat Genet"},{"key":"3086_CR21","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1016\/s0960-9822(02)01075-8","volume":"12","author":"PM Holland","year":"2002","unstructured":"Holland PM, Willis CR, Kanaly S et al (2002) RIP4 is an ankyrin repeat-containing kinase essential for keratinocyte differentiation. Curr Biol 12:1424\u20131428. https:\/\/doi.org\/10.1016\/s0960-9822(02)01075-8","journal-title":"Curr Biol"},{"key":"3086_CR22","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/jid.2009.223","volume":"130","author":"RB Rountree","year":"2010","unstructured":"Rountree RB, Willis CR, Dinh H et al (2010) RIP4 regulates epidermal differentiation and cutaneous inflammation. J Invest Dermatol 130:102\u2013112. https:\/\/doi.org\/10.1038\/jid.2009.223","journal-title":"J Invest Dermatol"},{"key":"3086_CR23","doi-asserted-by":"publisher","DOI":"10.31083\/j.fbl2812368","volume":"28","author":"L Hua","year":"2023","unstructured":"Hua L, Wu JH, Xu JY et al (2023) RIPK4 promotes cell invasion and the epithelial-mesenchymal transition in ovarian cancer. Front Biosci (Landmark Ed) 28:368. https:\/\/doi.org\/10.31083\/j.fbl2812368","journal-title":"Front Biosci (Landmark Ed)"},{"key":"3086_CR24","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.3892\/ijo.2018.4269","volume":"52","author":"ZH Qi","year":"2018","unstructured":"Qi ZH, Xu HX, Zhang SR et al (2018) RIPK4\/PEBP1 axis promotes pancreatic cancer cell migration and invasion by activating RAF1\/MEK\/ERK signaling. Int J Oncol 52:1105\u20131116. https:\/\/doi.org\/10.3892\/ijo.2018.4269","journal-title":"Int J Oncol"},{"key":"3086_CR25","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1093\/embo-reports\/kvf236","volume":"3","author":"E Meylan","year":"2002","unstructured":"Meylan E, Martinon F, Thome M et al (2002) RIP4 (DIK\/PKK), a novel member of the RIP kinase family, activates NF-\u03baB and is processed during apoptosis. EMBO Rep 3:1201\u20131208. https:\/\/doi.org\/10.1093\/embo-reports\/kvf236","journal-title":"EMBO Rep"},{"key":"3086_CR26","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/nrc780","volume":"2","author":"M Karin","year":"2002","unstructured":"Karin M, Cao Y, Greten FR et al (2002) NF-\u03baB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2:301\u2013310. https:\/\/doi.org\/10.1038\/nrc780","journal-title":"Nat Rev Cancer"},{"key":"3086_CR27","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/j.ccell.2016.10.010","volume":"30","author":"SO Lim","year":"2016","unstructured":"Lim SO, Li CW, Xia W et al (2016) Deubiquitination and stabilization of PD-L1 by CSN5. Cancer Cell 30:925\u2013939. https:\/\/doi.org\/10.1016\/j.ccell.2016.10.010","journal-title":"Cancer Cell"},{"key":"3086_CR28","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.immuni.2017.08.010","volume":"47","author":"H Oh","year":"2017","unstructured":"Oh H, Grinberg-Bleyer Y, Liao W et al (2017) An NF-\u03baB transcription-factor-dependent lineage-specific transcriptional program promotes regulatory T cell identity and function. Immunity 47:450-465.e5. https:\/\/doi.org\/10.1016\/j.immuni.2017.08.010","journal-title":"Immunity"},{"key":"3086_CR29","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/nri.2017.142","volume":"18","author":"K Taniguchi","year":"2018","unstructured":"Taniguchi K, Karin M (2018) NF-\u03baB, inflammation, immunity and cancer: coming of age. Nat Rev Immunol 18:309\u2013324. https:\/\/doi.org\/10.1038\/nri.2017.142","journal-title":"Nat Rev Immunol"},{"key":"3086_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01562","volume":"10","author":"J Xu","year":"2020","unstructured":"Xu J, Wei Q, He Z (2020) Insight into the function of RIPK4 in keratinocyte differentiation and carcinogenesis. Front Oncol 10:1562. https:\/\/doi.org\/10.3389\/fonc.2020.01562","journal-title":"Front Oncol"},{"key":"3086_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2023.110938","volume":"113","author":"N Wronski","year":"2024","unstructured":"Wronski N, Madej E, Grabacka M et al (2024) RIPK4 downregulation impairs Wnt3A-stimulated invasiveness via Wnt\/\u03b2-catenin signaling in melanoma cells and tumor growth in vivo. Cell Signal 113:110938. https:\/\/doi.org\/10.1016\/j.cellsig.2023.110938","journal-title":"Cell Signal"},{"key":"3086_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02293","volume":"10","author":"X Li","year":"2019","unstructured":"Li X, Xiang Y, Li F et al (2019) WNT\/\u03b2-catenin signaling pathway regulating T cell-inflammation in the tumor microenvironment. Front Immunol 10:2293. https:\/\/doi.org\/10.3389\/fimmu.2019.02293","journal-title":"Front Immunol"},{"key":"3086_CR33","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-023-01274-z","volume":"24","author":"K Mortezaee","year":"2024","unstructured":"Mortezaee K (2024) WNT\/\u03b2-catenin regulatory roles on PD-(L)1 and immunotherapy responses. Clin Exp Med 24:15. https:\/\/doi.org\/10.1007\/s10238-023-01274-z","journal-title":"Clin Exp Med"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03086-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-026-03086-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03086-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T16:35:49Z","timestamp":1784997349000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-026-03086-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,9]]},"references-count":33,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["3086"],"URL":"https:\/\/doi.org\/10.1007\/s10147-026-03086-z","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,9]]},"assertion":[{"value":"25 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Eiji Oki reports research funding from Guardant Health, Inc. and honoraria from Ono Pharm., Takeda Pharm., Bayer, Chugai Pharm., Taiho Pharm., Eli Lilly Japan, and Bristol-Myers Squibb. All remaining authors declare no conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Approval of the research protocol by an Institutional Reviewer Board: Approval of the study protocol was obtained from the Institutional Review Board of Kyushu University (IRB No. 22003\u201303). All procedures were performed in compliance with relevant laws and institutional guidelines and have been approved by the appropriate institutional committee. Informed consent: Informed consent was obtained via an opt-out procedure, as described at\n                      \n                      . Participants were not provided the option to decline participation.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}